Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4183.30 +0.3% SILVER 57.19 +0.1% COPPER 6.56 +0.1% OIL 98.92 +1.0% PALLADIUM 1114.00 −1.3% CCMM 0.540 +11.3% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.640 −1.5% LIB 0.700 −2.8% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.770 +1.3% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5% SLG 5.57 −2.5% CASA 0.060 +0.0% DRY 0.220 +2.3% GOLD 4183.30 +0.3% SILVER 57.19 +0.1% COPPER 6.56 +0.1% OIL 98.92 +1.0% PALLADIUM 1114.00 −1.3% CCMM 0.540 +11.3% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.640 −1.5% LIB 0.700 −2.8% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.770 +1.3% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5% SLG 5.57 −2.5% CASA 0.060 +0.0% DRY 0.220 +2.3%
Earnings

Cannara Biotech to release fiscal 2025 results Nov. 24

By The Northwire Desk — AI Analysis Nov 17, 2025 · 16:45 LOVE · 1.61 Cannara Biotech Inc
LOVE · Price

Executive Summary

  • Cannara Biotech Inc. will release its financial results for the fiscal fourth quarter and fiscal year ended August 31, 2025, on November 24, 2025.
  • An earnings webcast will be hosted by CEO Zohar Krivorot and CFO Nicholas Sosiak on the same day at 11 a.m. ET.
  • The company announced the passing of long-serving board member Jack M. Kay, who joined the board in 2019.

Key Details

  • Financial Release Date: November 24, 2025, at 7 a.m. ET.
  • Reporting Period: Fiscal Q4 2025 and Fiscal Year 2025 (ended August 31, 2025).
  • Webcast Details:
    • Date: Monday, November 24, 2025.
    • Time: 11 a.m. ET.
    • Format: Prepared remarks followed by a Q&A session.
    • Registration: Via the company's website event section.
    • Questions: Investors encouraged to submit in advance to [email protected]; priority given to email submissions.
  • Board Update:
    • Announcement of the passing of Jack M. Kay.
    • Mr. Kay served on the board since 2019.
    • Professional Background: 35 years at Apotex Inc. (CEO, COO, President, Vice-Chairman); Chairman of Helix Biopharma Corp. and Cangene Corp.; Director of Barr Pharmaceuticals Inc.; Chairman of Humber River Regional Hospital.

Notable Quotes

  • "Cannara would also like to announce with great sadness the passing of Jack M. Kay, a long-serving and highly respected member of the board of directors."
  • "The corporation extends its deepest condolences to Mr. Kay's family and expresses its sincere gratitude for his years of service and meaningful contributions to Cannara."
Read the original news release →

More from Cannara Biotech Inc

May 06, 2026 · 08:00

Cannara Consolidates Quebec Operations

M&A / Property Apr 14, 2026 · 07:00

Cannara Biotech Confirms Profitability Amidst Revenue Growth Deceleration

Earnings Apr 07, 2026 · 07:00

Cannara Biotech Inc.

Earnings Feb 26, 2026 · 08:00

Cannara Announces Graduation to the Toronto Stock Exchange

Regulatory Feb 04, 2026 · 17:47

Cannara Biotech closes $6.3-million private placement

Financings Feb 04, 2026 · 08:00

Cannara Announces Strategic C$6.3 Million Non-Brokered Private Placement Priced at C$2.10 per Common Share

Financings